NewsBenzingaRegeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M Benzinga 2026.10.06 11:58 (GMT+0) Open on Benzinga Other news Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $42 Eos Energy Enterprises Now Expects FY26 Revenue In Lower Half Of Its $300M To $350M Range CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings Mizuho Maintains Outperform on Equifax, Lowers Price Target to $185
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion
CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings
